Drugs.com - FDA MedWatch Alerts

FDA Clarifies Policies for Compounders as National GLP-1 Supply Begins to Stabilize

Audience: Industry October 2, 2024 -- The U.S. Food and Drug Administration has determined the shortage of tirzepatide injection, a glucagon-like peptide 1 (GLP-1) medication, has been resolved. Tirzepatide injection has been in shortage since 2022...

Feb 9, 2025 - 21:44
 0
FDA Clarifies Policies for Compounders as National GLP-1 Supply Begins to Stabilize
Audience: Industry October 2, 2024 -- The U.S. Food and Drug Administration has determined the shortage of tirzepatide injection, a glucagon-like peptide 1 (GLP-1) medication, has been resolved. Tirzepatide injection has been in shortage since 2022...
Read More

Tags:

Previous Article

FDA is Alerting Patients and Health Care Professionals About the Voluntary Withd...

Next Article

Gilead Issues Voluntary Nationwide Recall of One Lot of Veklury (Remdesivir) for...

Related Posts

Main Products, Inc. Issues Recall of Umary Acido Hialuronico, Suplemento Alimenticio Due to the Presence of Undeclared Drug Ingredients

Main Products, Inc. Issues Recall of Umary Acido Hialur...

Feb 9, 2025  0

Do Not Purchase or Use Skin-Cap Aerosol Spray Products Because They May Be Harmful to Your Health

Do Not Purchase or Use Skin-Cap Aerosol Spray Products ...

Feb 9, 2025  0

FDA, FTC Continue Joint Effort to Protect Consumers Against Companies Illegally Selling Copycat Delta-8 THC Food Products

FDA, FTC Continue Joint Effort to Protect Consumers Aga...

Feb 9, 2025  0